Milivoj Piletič

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017 · 414 citations

Sustain 4, Diabetes Management, Insulin-naive Patients +8

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study

J‐F. Blicklé, Nicolae Hâncu, Milivoj Piletič et al. · Diabetes Obesity and Metabolism · 2008 · 53 citations

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: <scp>A</scp> randomized, 18‐week, open‐label, phase 3 trial (onset 3)

Helena W. Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez et al. · Diabetes Obesity and Metabolism · 2017 · 44 citations · Full text

Weight change upon once‐daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin‐naïve individuals with type 2 diabetes: results from the <scp>DIET</scp> trial

Kevin D. Niswender, Milivoj Piletič, Henning Andersen et al. · Diabetes Obesity and Metabolism · 2013 · 15 citations · Full text

Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation

Lawrence A. Leiter, N. P. Trubitsyna, Milivoj Piletič et al. · Diabetes Research and Clinical Practice · 2015 · 13 citations

Release Gliclazide Formulation, Diabetes Management, Medicine +7